Thor Medical ASA (OSL:TRMED)
Norway
· Delayed Price · Currency is NOK 2.415
-0.040 (-1.63%)
Apr 25, 2025, 1:43 PM CET
Thor Medical ASA Company Description
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway.
It processes by separation of natural occurring radioactive decay products from thorium. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium.
The company was incorporated in 2009 and is headquartered in Oslo, Norway.
Thor Medical ASA
| Country | Norway |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Jasper Kurth |
Contact Details
Address: Karenslyst allE 9C Oslo, 0278 Norway | |
| Phone | 47 97 41 40 00 |
| Website | thormedical.no |
Stock Details
| Ticker Symbol | TRMED |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0010597883 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jasper Kurth | Chief Executive Officer |
| Brede Ellingsæter | Chief Financial and Operating Officer |
| Dr. Sindre Hassfjell | Chief Technology Officer |
| Dr. Alf Bjørseth Ph.D. | Executive Vice President of Business Development and Strategic Advisor |
| Astrid Liland | Executive Vice President of HSEQ |
| Sven Røst | Vice President of Communications |